Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma

J Clin Oncol. 2013 Jul 1;31(19):e312-5. doi: 10.1200/JCO.2012.45.9438. Epub 2013 May 20.

Authors

Friederike Hunstig¹, Jakob Hammersen, Christa Kunert, Iver Petersen, Hartmut Merz, Anita Glaser, Ulf Teichgräber, Andreas Hochhaus, Paul La Rosée

Affiliation

¹ Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany. [email protected]

PMID: 23690428
DOI: 10.1200/JCO.2012.45.9438

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antigens, CD20 / drug effects*
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / analysis
Biomarkers, Tumor / genetics*
Flow Cytometry
Humans
Induction Chemotherapy
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / genetics
Lymphoma, Mantle-Cell / pathology
Male
Molecular Targeted Therapy / methods*
Oncogene Proteins, Fusion / analysis
Oncogene Proteins, Fusion / drug effects
Oncogene Proteins, Fusion / genetics*
Risk Assessment
Risk Factors
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antigens, CD20
Antineoplastic Agents
Biomarkers, Tumor
IGH-CCND1 fusion protein, human
Oncogene Proteins, Fusion
ofatumumab